Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for the use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
If this recommendation is adopted by the European Commission, Veklury will become the first authorised antiviral treatment for COVID-19 across all stages of renal disease.
Around 75 million people in Europe suffer from chronic kidney disease (CKD), with advanced CKD and end-stage kidney disease (ESKD) patients being highly vulnerable to COVID-19. Mortality rates in this population can reach 21-25%.
Previous restrictions on Veklury use among patients with severe renal impairment were due to insufficient data. The positive opinion is based on a Phase 1 pharmacokinetic study and the Phase 3 REDPINE trial, which demonstrated the safety of Veklury in COVID-19 patients with severe renal impairment.
Veklury is the only antiviral in the European Economic Area (EEA) indicated for both the treatment of COVID-19 in adult and adolescent patients who do not require supplemental oxygen and are at increased risk of developing severe COVID-19, as well as adults, adolescent and paediatric patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation).
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA